ALX Oncology announced the appointment of Dr. Barbara Klencke as Interim Chief Medical Officer.
Dr. Klencke brings extensive experience in oncology drug development and a track record of success in leading clinical programs.
The appointment comes as Dr. Alan Sandler resigns from the role of Chief Medical Officer to return to the Company's Board of Directors.
Dr. Barbara Klencke Appointed
Dr. Klencke appointed as Interim Chief Medical Officer at ALX Oncology.
Dr. Alan Sandler Resigns
Dr. Sandler steps down from the role of Chief Medical Officer and returns to the Board of Directors.
Experience in Cancer Innovation
Dr. Klencke's extensive expertise positions her to lead the Company's development milestones.
- Dr. Klencke's appointment aims to drive the development strategy of ALX Oncology.
- The Company expects her leadership to advance the evorpacept and ALX2004 clinical programs effectively.
ALX Oncology's strategic decision to appoint Dr. Klencke reflects a focus on advancing cancer therapies and achieving key milestones.